| CASSAVA SCIENCES DL-,001 |
| USA |
| Gesundheit |
| US14817C1071 / A2PGL8 |
| PX91 (Frankfurt) / SAVA (NASDAQ) |
| FRA:PX91, ETR:PX91, PX91:GR, NASDAQ:SAVA |
| - |
| https://www.cassavascienc.. |
|
Cassava Sciences Inc. is a clinical-stage biotechnology company focused on developing novel treatments for central nervous system disorders. Its primary product candidate, simufilam, is an investigational oral small molecule drug currently advancing ..
>Volltext.. |
| 71.98 Mio. EUR |
| -9.29 Mio. EUR |
| - |
| -81.78 Mio. EUR |
| -78.81 Mio. EUR |
| -1.63 EUR |
| - |
| 82.73 Mio. EUR |
| -27.94 Mio. EUR |
| 2.18 |
| - |
| -229.41% |
| - |
| - |
| - |
| - |
| CASSAVA SCIENCES |
| 05.04.26 |
|